Program EADA 2021
The program on 18 November consists of 3 building blocks. Registration for lectures in one or more of the various blocks is now open:
I: Setting the scene: Corporates, Authorities & globally active Organisations
II: Technology and Product Updates in AMR: Academia, Start-ups & SMEs
III: Accelerating AMR R&D: Initiatives to boost national / global AMR R&D
Preliminary program:
| TIME: | I: SETTING THE SCENE OF AMR R&D | Presenting: | Affiliation: |
|---|---|---|---|
| 09:30 | Welcome | Dr Maarten van Dongen | AMR Insights (Netherlands) |
| 09:40 | KEY NOTE LECTURE by MERCK / MSD: title to follow | TBC | Merck / MSD (USA, Netherlands) |
| 10:00 | iiCON: Delivering Solutions for Integrated Solutions in AMR | Dr Becky Jones-Phillips | Liverpool School of Tropical Medicine (UK) |
| 10:20 | – Coffee break – | ||
| 10:30 | |||
| 10:50 | Antimicrobial Resistance in Zambia: A Systematic Review | Dr Avis Nowbuth | Pan-African Organisation for Health Education and Research (USA) |
| 11:10 | To be communicated | Dr Maneesh Paul | Acharya Institutes (India) |
| 11:30 | |||
| 11:50 | |||
| 12:10 | |||
| 12:30 | Concluding remarks on the morning program | Dr Maarten van Dongen | AMR Insights (Netherlands) |
| 12:35 | – Lunch break – | ||
| II: TECHNOLOGY AND PRODUCT UPDATES IN AMR | |||
| 01:00 | Use of bacteriophages in Animal Health | Dr Viviana Clavijo | Sciphage (Colombia) |
| 01:20 | A novel series of ruthenium antimicrobial compounds | Dr Kirsty Smitten | Metallobio (UK) |
| 01:40 | Two exciting late stage clinical assets and a range of earlier research programmes | Dr Daniel Hynes | Destiny Pharma (UK) |
| 02:00 | Tears hold a possibility to fight ABR | Dr Richard Stead | Qures Goup (UK) |
| 02:20 | A rapid, low cost, antibiotic susceptibility test for urinary tract infections | Dr Stuart Hannah | University of Strathclyde/ Microplate Dx (UK) |
| 02:40 | Novel non-pharmaceutical approach to prevent and control of bacterial infections without giving rise to AMR | Dr Vipula Tailor | Sonix Medical Devices, Inc (USA) |
| 03:00 | Fighting MDR Neisseria gonorrhoeae with novel massive polypharmacology | Dr Pascal Mayer | Alphanosos (F) |
| 03:20 | Antimicrobial susceptibility prediction, using direct-from-sample whole genome sequencing | Dr Ronda Taylor | Day Zero Diagnostics (USA) |
| 03:40 | |||
| 03:50 | – Coffee break – | ||
| III: ACCELERATING AMR R&D | |||
| 04:00 | Supporting innovators to fight drug-resistant bacterial infections | Dr Douglas Haggstrom | INCATE (Switzerland) |
| 04:20 | Horizon Europe grants aimed at R&D projects in the space of AMR | Dr Vlad Grecu | Catalyze Group (Netherlands) |
| 04:40 | Creating a large collection of chemical matter specifically targeting Gram-negative antimicrobial drug discovery | Dr. Bruce Blough | CC4CARB / NIH NIAID (USA) |
| 05:00 | Delivering drug and/or diagnostic in the areas of Neglected Diseases | Dr Shridhar Narayanan | Foundation for Neglected Disease Research (India) |
| 05:10 | State-Of-The-Art Platform Technologies essential for success and leadership in the field of AMR | Dr Taslimarif Saiyed | C-CAMP (India) |
| 05:20 | JPIAMR-VRI a dynamic network of AMR research facilities to share and use resources and improve dialogue amongst researchers, funders and policy makers | Dr Shawon Lahiri | JPIAMR (EU) |
| 05:40 | Closing remarks | Dr Maarten van Dongen | AMR Insights (Netherlands) |
